Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Homocystinuria due to methylene tetrahydrofolate reductase (MTHFR) deficiency is a metabolic disorder characterized by neurological manifestations.
Features include very common findings: Atypical behavior, Difficulty walking (gait disturbance), Homocystinuria, and Hyperhomocystinemia and others; and common findings: Seizure, Psychotic episodes, Ataxia, and Mental deterioration and others. 53 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 28 | Stroke, Paresthesia, Atypical behavior |
Muscles | 6 | Muscle weakness, Lower limb muscle weakness, Atrophy of the spinal cord |
Eyes | 3 | Abnormality of the eye, Nystagmus, Damage to the optic nerve (optic atrophy) |
Heart and blood vessels | 2 | Stroke, Thromboembolic stroke |
Arms and legs | 2 | Lower limb spasticity, Lower limb muscle weakness |
Head and neck | 1 | Microcephaly |
Nervous system (morphological) | 1 | Morphological central nervous system abnormality |
Growth and development | 1 | Failure to thrive |
Lungs and breathing | 1 | Apnea |
Digestive system | 1 | Feeding difficulties in infancy |
Pregnancy and birth | 1 | Generalized neonatal hypotonia |
MTHFR encodes methylenetetrahydrofolate reductase (656 aa). Catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a cosubstrate for homocysteine remethylation to methionine. Highest expression in Ovary (25.6 TPM) and Nerve Tibial (24.0 TPM).
Homocystinuria due to methylene tetrahydrofolate reductase deficiency is caused by mutations in the MTHFR gene on chromosome 1.
MTHFR is classified as a druggable target (Clinically Actionable and Enzyme categories) with score 5.6.
No consensus clinical diagnostic criteria for homocystinuria due to deficiency of N(5,10)-methylenetetrahydrofolate reductase (MTHFR) activity have been published.
A diagnosis of homocystinuria due to deficiency of N(5,10)-MTHFR activity may be suspected due to an abnormal newborn screening (NBS) result prior to onset of suggestive findings or may be considered because of symptoms of homocystinuria due to deficiency of N(5,10)-MTHFR activity .
NBS for homocystinuria due to deficiency of N(5,10)-MTHFR activity is primarily based on use of dried blood spots collected between 24 and 72 hours after birth to quantify methionine and homocysteine concentrations by tandem mass spectrometry (MS/MS). For information on NBS by state in the US, see www.
Source: GeneReviews — "Homocystinuria due to Deficiency of N(5,10)-Methylenetetrahydrofolate Reductase Activity"
Genetic testing for MTHFR is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for homocystinuria due to methylene tetrahydrofolate reductase deficiency has been reported in the published literature.
No approved treatments are currently available for homocystinuria due to methylene tetrahydrofolate reductase deficiency. The disease remains an area of unmet medical need.
No clinical practice guidelines for homocystinuria due to deficiency of N(5,10)-methylenetetrahydrofolate reductase (MTHFR) activity have been published. In the absence of published guidelines, the following recommendations are based on the authors' personal experience managing individuals with this disorder.
To establish the extent of disease and needs in an individual diagnosed with homocystinuria due to deficiency of N(5,10)-MTHFR activity, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 4.
Homocystinuria due to Deficiency of N(5,10)-Methylenetetrahydrofolate Reductase Activity: Recommended Evaluations Following Initial Diagnosis
System/Concern | Evaluation | Comment
| • Measure plasma homocysteine concentration plasma amino acids to assess methionine concentration.
Measure CSF 5-MTHF CSF methionine concentration.
|
| • Assessment for respiratory compromise
Apnea monitoring
Sleep study
| • Regular eval is important to identify any breathing difficulties that may arise due to the disorder.
Apnea monitoring is essential for newborns or infants, as homocystinuria can be assoc w/apnea other respiratory issues.
Growth/
| • Assessment of growth caloric intake
Feeding team eval as needed
| • To incl eval of aspiration risk nutritional status
Consider eval for gastrostomy tube placement in persons w/dysphagia /or aspiration risk.
| Neurologic eval |...
Source: GeneReviews — "Homocystinuria due to Deficiency of N(5,10)-Methylenetetrahydrofolate Reductase Activity"
1 trial found
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended. Table 7. Homocystinuria due to Deficiency of N(5,10)-Methylenetetrahydrofolate Reductase Activity: Recommended Surveillance
System/Concern | Evaluation | Frequency |
|---|---|---|
Biochemical | Measure plasma homocysteine concentration plasma amino acids to assess methionine concentration | Every 3-4 mos Measure CSF 5-MTHF CSF methionine concentration. |
Psychiatric | Assessment for anxiety, ADHD, ASD, aggression, self-injury | Annually or if symptomatic |
Motor gait abnormalities | Physical medicine, OT/PT assessment of mobility, self-help skills | At each visit |
Neurovascular manifestations | Neurovascular assessment (e.g., brain imaging, risk of stroke) | Annually or if concerns arise |
Family/Community | Assess family need for social work support (e.g., palliative/respite care, home nursing, other local resources), care coordination, or follow-up genetic counseling if new questions arise (e.g., family planning). | At each visit ADHD = attention-deficit/hyperactivity disorder; ASD = autism spectrum disorder; CSF = cerebrospinal fluid; MTHF = methyltetrahydrofolate; OT = occupational therapy; PT = physical therapy |
Source: GeneReviews — "Homocystinuria due to Deficiency of N(5,10)-Methylenetetrahydrofolate Reductase Activity"
Phenotype severity distribution: 10 very common features, 9 common features.
Estimated prevalence: Unknown (Unknown prevalence).
1 clinical trial registered. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
18 publications have been identified in PubMed for homocystinuria due to methylene tetrahydrofolate reductase deficiency. Research spans Case Report / Case Series (33%), Review / Meta-Analysis (17%), and Basic Science / Preclinical (17%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 6 | 33% |
Research summaries | 3 | 17% |
Laboratory research | 3 | 17% |
Disease patterns and progression | 3 | 17% |
Other research | 2 | 11% |
Testing and diagnosis research | 1 | 6% |
Olivieri G (2026). [PMID: 42231716](https://pubmed.ncbi.nlm.nih.gov/42231716/). *J Inherit Metab Dis*. [Review / Meta-Analysis]
Li YX (2026). [PMID: 41557084](https://pubmed.ncbi.nlm.nih.gov/41557084/). *Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology*. [Case Report / Case Series]
Avula SN (2026). [PMID: 41423519](https://pubmed.ncbi.nlm.nih.gov/41423519/). *Indian J Pediatr*. [Other]
Blomgren LKM (2026). [PMID: 41758688](https://pubmed.ncbi.nlm.nih.gov/41758688/). *Biochemistry*. [Review / Meta-Analysis]
Barda D (2026). [PMID: 41963776](https://pubmed.ncbi.nlm.nih.gov/41963776/). *J Neurodev Disord*. [Basic Science / Preclinical]
Sapir H (2025). [PMID: 40057124](https://pubmed.ncbi.nlm.nih.gov/40057124/). *Neurobiology of disease*. [Basic Science / Preclinical]
Loftus E (2025). [PMID: 40575625](https://pubmed.ncbi.nlm.nih.gov/40575625/). *Clin Case Rep*. [Case Report / Case Series]
Sunoki K (2025). [PMID: 40596302](https://pubmed.ncbi.nlm.nih.gov/40596302/). *Scientific reports*. [Case Report / Case Series]
Li W (2025). [PMID: 39571660](https://pubmed.ncbi.nlm.nih.gov/39571660/). *Gene*. [Diagnostic / Biomarker]
Habib A (2024). [PMID: 39322052](https://pubmed.ncbi.nlm.nih.gov/39322052/). *Clinical biochemistry*. [Case Report / Case Series]
Data assembled from 9 of 12 sources · Last updated Oct 3, 2026, 5:10 PM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center